The Latest

  • office red
    Image attribution tooltip
    Stock via Getty Images
    Opinion

    Hybrid work is here to stay — here’s how leaders should adjust

    Executives across the life sciences share their tips for navigating the new norm of remote work.

  • Close up of a woman's hand holding a smart phone with a heart icon.
    Image attribution tooltip
    iStock via Getty Images

    4 pioneering social media campaigns in pharma this year

    The key to a great social media campaign is often simplicity, and these pharma companies hit the nail on the head with unique strategies that aim to educate. 

  • Artificial intelligence in healthcare
    Image attribution tooltip
    ArtemisDiana via Getty Images

    Is AI just hype or a real revolution in pharma? It’s complicated

    Artificial intelligence can be a useful tool and will likely augment many processes in biopharma — but it's still early days, and hype is rampant.

  • Francisco Barriga and Kaloyan Tsanov of the Sloan Kettering Institute
    Image attribution tooltip
    Permission granted by Memorial Sloan Kettering Cancer Center

    To explore cancer’s genetic mysteries, researchers turn to ‘MACHETE’

    A new CRISPR-based tool could help scientists understand and better treat cancer by revealing the complex genetic mutations that occur.

  • Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Janssen’s Najat Khan

    Janssen’s Najat Khan, Ph.D., chief data science officer and global head of strategy and operations, shares how the company is using next-gen tech to ‘reimagine’ medicine.

  • HLTH conference 2022
    Image attribution tooltip
    Meagan Parrish/PharmaVoice

    #HLTH: ‘Unicorns are real’ — and here’s how they can navigate a challenging biotech market

    Venture capitalists tackle ways companies can stay afloat while the market’s turbulent waters rise.

  • Professional headshot of Sana Alajmovic.
    Image attribution tooltip

    Permission granted by Sana Alajmovic

    Profile

    A ‘bold vision’ to prevent diabetes

    Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts. 

  • COVID vaccine development
    Image attribution tooltip
    iStock via Getty Images

    4 ways to bring COVID’s ‘warp speed’ to the next era of drug development

    An IQVIA Institute for Human Data Science report outlines how companies can improve communication, recruitment, data and investing strategies to accelerate clinical trial timelines.

  • washington flag
    Image attribution tooltip
    iStock via Getty Images
    Opinion

    Why the IRA will drive up the country’s drug bill — not lower it

    On the surface, the Inflation Reduction Act is designed to lower drug prices, but its impact on innovation incentives could produce a landscape of new medicines that are costlier for patients.

  • Glen de Vries blue origin
    Image attribution tooltip
    Permission granted by Medidata
    Q&A

    The legacy of Glen de Vries: Our last interview with the pioneering entrepreneur

    Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.

  • U.S. economy contracted for second consecutive quarter
    Image attribution tooltip
    Baris-Ozer via Getty Images

    3 ways pharma can weather a recession

    If “winter is coming” in the form of a recession, pharmas can take advantage of an inherent resiliency by crushing these three fundamentals.

  • Lene Oddershede
    Image attribution tooltip
    Permission granted by Lene Oddershede
    Q&A

    Novo Nordisk’s quantum bet on ‘world changing’ computing

    Behind the pharma giant’s plans to build the first quantum computer by 2034 to accelerate drug development.

  • Professional headshot of Joe Landolina
    Image attribution tooltip

    Permission granted by Cresilon

    Profile

    This plant-based gel stops bleeding in seconds — and might have potential in drug delivery

    29-year-old biotech founder Joe Landolina is hoping to capitalize on major possibilities in the human health market through his startup Cresolin and just inked a research partnership with Walter Reed.

  • Tier Bryant, 82VS
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: 82VS’s Trier Bryant

    Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Not every leader makes it their mission to go where the fire ...

  • Rami Elghandour headshot
    Image attribution tooltip
    Permission granted by Rami Elghandour
    Profile

    Chasing that ‘Time magazine cover potential’

    Rami Elghandour was already retired. Then CAR-T specialist Arcellx lured him back into the industry to try to change the world.

  • IV infusion
    Image attribution tooltip
    Amornrat Phuchom via Getty Images

    While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help

    Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.

  • A creative image depicting empty voting booths on election day.
    Image attribution tooltip
    adamkaz / iStock / Getty Images Plus via Getty Images

    What pharma could gain — or lose — from the midterms

    With control of the House and Senate both up for grabs, and potentially leaning Republican, here’s what the midterm elections mean for pharma. 

  • MRI Brain scan
    Image attribution tooltip
    Stock via Getty Images

    After numerous setbacks, here’s where the Huntington’s pipeline stands

    A look at emerging treatments and where there’s hope for patients.

  • Disabilities
    Image attribution tooltip
    Stock via Getty Images
    Q&A

    The other ‘D’ in DE&I

    How companies can work to include people with disabilities into broader equity aims.

  • nerve signals in brain
    Image attribution tooltip
    Stock via Getty Images

    Acumen cruises into the fast lane with novel Alzheimer’s treatment

    The company’s distinct amyloid-beta target, which just won a fast track designation, could give it an edge over the competition.

  • Cat
    Image attribution tooltip
    Christopher Furlong / Staff via Getty Images

    ‘Zombie’ cells, Shkreli and cats — new research in toxoplasmosis and how the three are connected

    Toxoplasmosis is carried by about a third of the world’s population, but effective drugs are lacking — now researchers have discovered a key infection element that could lead to better treatment.

  • In the distance, exhaust plumes billow over seven power plants. The reflection of the power plants can be seen in a lake.
    Image attribution tooltip
    Sean Gallup / Staff via Getty Images

    How Europe’s energy crisis is impacting pharma

    Inflationary pressures and rising energy costs could further expedite the movement of generics manufacturing from Europe to Asia if governments don’t step in.

  • Gulden Mesera wow pix
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: City of Hope’s Gulden Mesara

    Charged with bridging the 100-year-old research center to its future mission of holistic patient cancer care, Mesara is bringing decades of experience in communications and culture creation.

  • diagram of man, doctor, phone, tablet
    Image attribution tooltip
    Retrieved from Google image.

    While DCTs get all the hype, some industry insiders say the future is a digital hybrid

    Leaders at Veeva believe the wording around decentralized trials has been exaggerated, and that a bigger-picture outlook is important as the pandemic winds down.

  • tuberculosis scan
    Image attribution tooltip
    Spencer Platt via Getty Images
    Q&A

    Tuberculosis patients haven’t seen new treatments in 40 years – now Merck and Gates MRI have teamed up to change that

    The Bill & Melinda Gates Medical Research Institute’s clinical development leader talks about its new licensing deal with Merck.